glp-1 agonist cardiovascular outcomes Results of trials comparing receptor GLP-1 receptor agonists and cardiovascular

Description

In adipose tissue, GLP-1 receptors are directly expressed and activation impacts apoptosis and preadipocyte proliferation, as well as fat deposition through regulation of lipolysis, fatty acid oxidation, and adipocyte differentiation

Incidence of injection site reactions is about 4%

Previously prescribed to treat blood sugar spikes in diabetes patients, glucagon-like peptide 1 (GLP-1) drugs stimulate release of insulin, keeping blood sugar levels low

Activation of GLP-1 receptor promotes bone marrow stromal cell osteogenic differentiation through -catenin

For example, in the treatment of Alzheimers diseases (AD) and Parkinsons diseases (PD), GLP-1RAs have shown potential in slowing disease progression, while their anti-inflammatory properties offer new hope for conditions such as osteoarthritis (OA), rheumatoid arthritis (RA) and cardiovascular diseases